Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians

Bedaquiline (BDQ) use for all age groups in drug-resistant (DR) tuberculosis (TB) regimens for children may be shorter, safer, and more effective. However, the emergence of BDQ resistance reports soon after its introduction is alarming. We report the case of a 17-year-old boy, initially diagnosed with Rifampicin-resistant (RR)-TB and developed BDQ resistance during the treatment. To the best of our knowledge, this is the first report of BDQ resistance in pediatric.